Figure 1
![Figure 1. cFIX-R338L antigen and activity levels over time in HB dogs treated with AAV6-cFIX-R338L. Three adult male HB dogs (M55 [A], M59 [B], and N07 [C]) were administered 2.5-3 × 1012 vg/kg of AAV6-cFIX-R338L by peripheral transvenular delivery to the skeletal muscle. cFIX antigen levels were measured over time by ELISA (□), and cFIX activity levels were measured by activated partial thromboplastin time (●). Black arrows indicate weekly challenges with pooled normal canine plasma (100 mL). (D) PBMCs collected from M59 and N07 after the fourth challenge were subjected to IFN-γ ELISpot analysis after stimulation with AAV6 capsid, cFIX protein, or overlapping peptides spanning the 338 region (RATCLR/LSTKFTIYNM, LKVPVDRATCLR/LST).](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/120/23/10.1182_blood-2012-06-440123/4/zh89991297480001.jpeg?Expires=1735822457&Signature=4Qjmb5HMzmCz1a4feNmIS4dgJyPpSEcHUbu7FCvYw4XM20OzoRwe6wZfuoaBLjjjZc0M3OVIbqWn647KL7ORchU-t8yLQ9wQJbkiMAWq3EfmjRnqAFtv~oy8hlwh3~s1QjGeN69q3uMvYcmyXENxtqUhFeBtBWUxAySmmsn~zXG9BaOanPP3qKLtwj8tG1hwDMLHtv-E~UlITUGrBpFpZGJAy-ogoYK2c4n6jhwGeP88-xaTichKN0wvP45oNzRrhwKod4m6uRfOA9F-Dlr09aI1dbQ~eHylhUVlVbgMYzPbkPnlplNCSVNzQdzdZUY2bfkvRYFJeQjbDBTf2qY5vw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
cFIX-R338L antigen and activity levels over time in HB dogs treated with AAV6-cFIX-R338L. Three adult male HB dogs (M55 [A], M59 [B], and N07 [C]) were administered 2.5-3 × 1012 vg/kg of AAV6-cFIX-R338L by peripheral transvenular delivery to the skeletal muscle. cFIX antigen levels were measured over time by ELISA (□), and cFIX activity levels were measured by activated partial thromboplastin time (●). Black arrows indicate weekly challenges with pooled normal canine plasma (100 mL). (D) PBMCs collected from M59 and N07 after the fourth challenge were subjected to IFN-γ ELISpot analysis after stimulation with AAV6 capsid, cFIX protein, or overlapping peptides spanning the 338 region (RATCLR/LSTKFTIYNM, LKVPVDRATCLR/LST).
